266 related articles for article (PubMed ID: 35640549)
1. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K; Yamazaki N
Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
[TBL] [Abstract][Full Text] [Related]
5. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
6. Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR; Mehnert JM
Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma.
Mori T; Izumi T; Doi R; Kamimura A; Takai S; Teramoto Y; Nakamura Y
Exp Dermatol; 2023 Mar; 32(3):276-289. PubMed ID: 36477933
[TBL] [Abstract][Full Text] [Related]
8.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
9. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A; Amaral T
Front Oncol; 2024; 14():1340408. PubMed ID: 38469235
[TBL] [Abstract][Full Text] [Related]
11. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy.
Gajón JA; Juarez-Flores A; De León Rodríguez SG; Aguilar Flores C; Mantilla A; Fuentes-Pananá EM; Bonifaz LC
Arch Med Res; 2022 Dec; 53(8):794-806. PubMed ID: 36460547
[TBL] [Abstract][Full Text] [Related]
13. Translational pathology, genomics and the development of systemic therapies for acral melanoma.
Chen YA; Teer JK; Eroglu Z; Wu JY; Koomen JM; Karreth FA; Messina JL; Smalley KSM
Semin Cancer Biol; 2020 Apr; 61():149-157. PubMed ID: 31689494
[TBL] [Abstract][Full Text] [Related]
14. Management of acral lentiginous melanoma: current updates and future directions.
Dugan MM; Perez MC; Karapetyan L; Zager JS
Front Oncol; 2024; 14():1323933. PubMed ID: 38390259
[TBL] [Abstract][Full Text] [Related]
15. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
16. Recent advancements in the diagnosis and treatment of acral melanoma.
Alhaskawi A; Ezzi SHA; Dong Y; Zhou H; Wang Z; Lai J; Yao C; Kota VG; Abdulla MHAH; Lu H
J Zhejiang Univ Sci B; 2024 Feb; 25(2):106-122. PubMed ID: 38303495
[TBL] [Abstract][Full Text] [Related]
17. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.
Gui J; Guo Z; Wu D
J Transl Med; 2022 Aug; 20(1):367. PubMed ID: 35974375
[TBL] [Abstract][Full Text] [Related]
18. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
Cho KK; Cust AE; Foo YM; Long GV; Menzies AM; Eslick GD
Melanoma Res; 2021 Oct; 31(5):482-486. PubMed ID: 34433196
[TBL] [Abstract][Full Text] [Related]
19. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
20. Emerging strategies to treat rare and intractable subtypes of melanoma.
Alicea GM; Rebecca VW
Pigment Cell Melanoma Res; 2021 Jan; 34(1):44-58. PubMed ID: 32274887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
